GlaxoSmithKline plc (GSK) Given Neutral Rating at J P Morgan Chase & Co
Several other equities research analysts also recently weighed in on the company. Deutsche Bank AG set a GBX 1,610 ($21.71) price objective on GlaxoSmithKline plc and gave the company a neutral rating in a report on Thursday. Shore Capital restated a hold rating on shares of GlaxoSmithKline plc in a research note on Wednesday. Berenberg Bank reiterated a buy rating and issued a GBX 1,835 ($24.74) price objective on shares of GlaxoSmithKline plc in a research report on Tuesday. Bryan, Garnier & Co reiterated a neutral rating and issued a GBX 1,710 ($23.06) price objective on shares of GlaxoSmithKline plc in a research report on Tuesday. Finally, Jefferies Group LLC cut their price objective on GlaxoSmithKline plc from GBX 1,750 ($23.59) to GBX 1,675 ($22.58) and set a buy rating for the company in a research report on Monday. Four research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and seven have issued a buy rating to the company. The company has an average rating of Hold and a consensus price target of GBX 1,698.52 ($22.90).
GlaxoSmithKline plc (GSK) traded up 0.41% during trading on Thursday, reaching GBX 1474.00. 5,726,851 shares of the company’s stock were exchanged. The stock has a 50-day moving average of GBX 1,503.38 and a 200-day moving average of GBX 1,606.97. The stock’s market capitalization is GBX 72.05 billion. GlaxoSmithKline plc has a 52 week low of GBX 1,444.00 and a 52 week high of GBX 1,745.56.
The firm also recently disclosed a dividend, which will be paid on Thursday, October 12th. Investors of record on Thursday, August 10th will be given a dividend of GBX 19 ($0.26) per share. The ex-dividend date is Thursday, August 10th. This represents a dividend yield of 1.23%.
In other GlaxoSmithKline plc news, insider Manvinder Singh Banga acquired 2,267 shares of the business’s stock in a transaction that occurred on Wednesday, July 26th. The stock was acquired at an average price of GBX 1,599 ($21.56) per share, with a total value of £36,249.33 ($48,873.30). Also, insider Patrick Vallance acquired 861 shares of the business’s stock in a transaction that occurred on Friday, July 14th. The shares were acquired at an average cost of GBX 1,618 ($21.81) per share, with a total value of £13,930.98 ($18,782.50). Insiders have purchased a total of 3,152 shares of company stock valued at $5,055,023 in the last three months.
About GlaxoSmithKline plc
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.